Vericel Corporation (VCEL)

Market Cap	2.82B
Revenue (ttm)	226.84M
Net Income (ttm)	3.55M
Shares Out	49.36M
EPS (ttm)	0.07
PE Ratio	778.11
Forward PE	139.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,608
Open	58.84
Previous Close	58.74
Day's Range	56.90 - 59.42
52-Week Range	32.31 - 61.49
Beta	1.72
Analysts	Strong Buy
Price Target	60.17 (+5.4%)
Earnings Date	Nov 7, 2024

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 1997
• Employees: 314
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL
• Website: https://vcel.com

Financial Performance

In 2023, Vericel's revenue was $197.52 million, an increase of 20.17% compared to the previous year's $164.37 million. Losses were -$3.18 million, -80.96% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price forecast is $60.17, which is an increase of 5.40% from the latest price.

Price Target

$60.17

(5.40% upside)

Analyst Consensus: Strong Buy